Ikarian Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ikarian Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-56,594	Closed	-$18.5M	–	170
2025 Q2	$18.5M	Buy	56,594 +25,000	+79%	+$6.92M	3.54%	4
2025 Q1	$8.53M	Buy	+31,594	New	+$8.12M	1.05%	14
2024 Q4	–	Sell	-8,741	Closed	-$2.4M	–	172
2024 Q3	$2.4M	Buy	+8,741	New	+$2.28M	0.34%	69
2024 Q2	–	Sell	-51,541	Closed	-$8.14M	–	114
2024 Q1	$7.7M	Buy	+51,541	New	+$8.6M	0.84%	40
2022 Q4	–	Sell	-2,800	Closed	-$560K	–	87
2022 Q3	$560K	Sell	2,800 -58,437	-95%	-$11.1M	0.11%	79
2022 Q2	$8.93M	Buy	61,237 +60,000	+4,850%	+$8.51M	1.63%	19
2022 Q1	$201K	Buy	1,237 +42	+4%	+$6.4K	0.03%	166
2021 Q4	$204K	Sell	1,195 -266	-18%	-$49.4K	0.03%	155
2021 Q3	$276K	Buy	+1,461	New	+$274K	0.02%	198

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Ikarian Capital's ALNY Position: Q3 2025 in Review

Ikarian Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 56,594 shares — an estimated $18.5M sold.

Ikarian Capital first reported a position in ALNY in Q3 2021 and held it in 9 quarters. The position peaked at $18.5M in Q2 2025. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

Ikarian Capital reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Ikarian Capital sold 56,594 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $18.5M.
Ikarian Capital first reported a position in Alnylam Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Ikarian Capital's Alnylam Pharmaceuticals position peaked at $18.5M in Q2 2025.
823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.